TY - JOUR
T1 - Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom
AU - Pebody, Richard
AU - Harris, Ross
AU - Kafatos, George
AU - Chamberland, Mary
AU - Campbell, Colin
AU - Nguyen-van-Tam, Jonathan
AU - Mclean, Estelle
AU - Andrews, Nicholas
AU - White, Peter
AU - Wynne-Evans, Edward
AU - Green, Jonathan
AU - Ellis, Joanna
AU - Wreghitt, Timothy
AU - Bracebridge, Samantha
AU - Ihekweazu, Chikwe
AU - Oliver, Isabel
AU - Smith, Gillian
AU - Hawkins, Colin
AU - Salmon, Roland
AU - Smyth, Brian
AU - Mcmenamin, Jim
AU - Zambon, Maria
AU - Phin, Nicholas
AU - Watson, John
PY - 2011/6
Y1 - 2011/6
N2 - The United Kingdom implemented a containment strategy for pandemic (H1N1) 2009 through administering antiviral agents (AVs) to patients and their close contacts. This observational household cohort study describes the effect of AVs on household transmission. We followed 285 confirmed primary cases in 259 households with 761 contacts. At 2 weeks, the confirmed secondary attack rate (SAR) was 8.1% (62/761) and significantly higher in persons <16 years of age than in those >50 years of age (18.9% vs. 1.2%, p<0.001). Early (<48 hours) treatment of primary case-patients reduced SAR (4.5% vs. 10.6%, p = 0.003). The SAR in child contacts was 33.3% (10/30) when the primary contact was a woman and 2.9% (1/34) when the primary contact was a man (p = 0.010). Of 53 confirmed secondary case-patients, 45 had not received AV prophylaxis. The effectiveness of AV prophylaxis in preventing infection was 92%.
AB - The United Kingdom implemented a containment strategy for pandemic (H1N1) 2009 through administering antiviral agents (AVs) to patients and their close contacts. This observational household cohort study describes the effect of AVs on household transmission. We followed 285 confirmed primary cases in 259 households with 761 contacts. At 2 weeks, the confirmed secondary attack rate (SAR) was 8.1% (62/761) and significantly higher in persons <16 years of age than in those >50 years of age (18.9% vs. 1.2%, p<0.001). Early (<48 hours) treatment of primary case-patients reduced SAR (4.5% vs. 10.6%, p = 0.003). The SAR in child contacts was 33.3% (10/30) when the primary contact was a woman and 2.9% (1/34) when the primary contact was a man (p = 0.010). Of 53 confirmed secondary case-patients, 45 had not received AV prophylaxis. The effectiveness of AV prophylaxis in preventing infection was 92%.
UR - http://www.scopus.com/inward/record.url?scp=79957668787&partnerID=8YFLogxK
U2 - 10.3201/eid/1706.101161
DO - 10.3201/eid/1706.101161
M3 - Article
AN - SCOPUS:79957668787
SN - 1080-6040
VL - 17
SP - 990
EP - 999
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 6
ER -
